Biopharmaceutical company focused on developing oral therapies for endocrine disorders and rare diseases.
Crinetics Pharmaceuticals, Inc. is a dynamic clinical stage pharmaceutical company dedicated to advancing therapies for rare endocrine diseases and endocrine-related tumors. At the forefront of its innovative pipeline is Paltusotine, a promising oral selective nonpeptide somatostatin receptor type 2 agonist. This lead product candidate has successfully completed phase III clinical trials for the treatment of acromegaly, demonstrating its potential to address significant unmet medical needs. Additionally, Paltusotine has completed phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs), highlighting its broad therapeutic potential.
In its commitment to innovation, Crinetics Pharmaceuticals is also advancing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist currently in phase I clinical trials. This candidate aims to address congenital hyperinsulinism, a rare pediatric disorder characterized by dysregulated insulin secretion. Furthermore, the company is developing CRN04894, an oral adrenocorticotrophic hormone antagonist currently in phase I clinical trials. This novel therapy is targeted at treating Cushing's syndrome and congenital adrenal hyperplasia, conditions that significantly impact patients' quality of life.
Founded in 2008 and headquartered in San Diego, California, Crinetics Pharmaceuticals comnbines cutting-edge research with a deep commitment to patient care. The company's robust pipeline and innovative approach underscore its dedication to transforming the treatment landscape for rare endocrine diseases. By leveraging its expertise and collaborative partnerships, Crinetics Pharmaceuticals aims to deliver impactful therapies that improve the lives of patients worldwide.
Driven by a vision to redefine standards of care in endocrinology, Crinetics Pharmaceuticals remains at the forefront of scientific discovery and therapeutic development. With a focus on rare and underserved patient populations, the company continues to pioneer groundbreaking solutions that address critical medical needs and enhance patient outcomes.